Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
1.
Am J Kidney Dis ; 2023 Nov 14.
Article in English | MEDLINE | ID: mdl-37972814

ABSTRACT

Providing high-quality patient-centered care is the central mission of dialysis facilities. Assessing quality and patient-centeredness of dialysis care is necessary for continuous dialysis facility improvement. Based predominantly on readily measured items, current quality measures in dialysis care emphasize biochemical and utilization outcomes, with very few patient-reported items. Additionally, current metrics often do not account for patient preferences and may compromise patient-centered care by limiting the ability of providers to individualize care targets, such as dialysis adequacy, based on patient priorities rather than a fixed numerical target. Developing, implementing, and maintaining a quality program using readily quantifiable data while also allowing for individualization of care targets that emphasize the goals of patients and their care partners provided the motivation for a September 2022 Kidney Disease Outcomes Quality Initiative (KDOQI) Workshop on Patient-Centered Quality Measures for Dialysis Care. Workshop participants focused on 4 questions: (1) What are the outcomes that are most important to patients and their care partners? (2) How can social determinants of health be accounted for in quality measures? (3) How can individualized care be effectively addressed in population-level quality programs? (4) What are the optimal means for collecting valid and robust patient-reported outcome data? Workshop participants identified numerous gaps within the current quality system and favored a conceptually broader, but not larger, quality system that stresses highly meaningful and adaptive measures that incorporate patient-centered principles, individual life goals, and social risk factors. Workshop participants also identified a need for new, low-burden tools to assess patient goals and priorities.

4.
Circulation ; 137(2): 134-143, 2018 01 09.
Article in English | MEDLINE | ID: mdl-29021322

ABSTRACT

BACKGROUND: In individuals with a low diastolic blood pressure (DBP), the potential benefits or risks of intensive systolic blood pressure (SBP) lowering are unclear. METHODS: SPRINT (Systolic Blood Pressure Intervention Trial) was a randomized controlled trial that compared the effects of intensive (target <120 mm Hg) and standard (target <140 mm Hg) SBP control in 9361 older adults with high blood pressure at increased risk of cardiovascular disease. The primary outcome was a composite of cardiovascular disease events. All-cause death and incident chronic kidney disease were secondary outcomes. This post hoc analysis examined whether the effects of the SBP intervention differed by baseline DBP. RESULTS: Mean baseline SBP and DBP were 139.7±15.6 and 78.1±11.9 mm Hg, respectively. Regardless of the randomized treatment, baseline DBP had a U-shaped association with the hazard of the primary cardiovascular disease outcome. However, the effects of the intensive SBP intervention on the primary outcome were not influenced by baseline DBP level (P for interaction=0.83). The primary outcome hazard ratio for intensive versus standard treatment was 0.78 (95% confidence interval, 0.57-1.07) in the lowest DBP quintile (mean baseline DBP, 61±5 mm Hg) and 0.74 (95% confidence interval, 0.61-0.90) in the upper 4 DBP quintiles (mean baseline DBP, 82±9 mm Hg), with an interaction P value of 0.78. Results were similar for all-cause death and kidney events. CONCLUSIONS: Low baseline DBP was associated with increased risk of cardiovascular disease events, but there was no evidence that the benefit of the intensive SBP lowering differed by baseline DBP. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01206062.


Subject(s)
Antihypertensive Agents/therapeutic use , Blood Pressure/drug effects , Hypertension/drug therapy , Acute Coronary Syndrome/epidemiology , Aged , Aged, 80 and over , Antihypertensive Agents/adverse effects , Diastole/drug effects , Female , Humans , Hypertension/diagnosis , Hypertension/mortality , Hypertension/physiopathology , Incidence , Male , Middle Aged , Myocardial Infarction/epidemiology , Puerto Rico , Renal Insufficiency, Chronic/epidemiology , Risk Factors , Time Factors , Treatment Outcome , United States
5.
Semin Dial ; 23(3): 324-9, 2010.
Article in English | MEDLINE | ID: mdl-20636926

ABSTRACT

Kidney transplantation is the treatment of choice for most patients with stage 5 chronic kidney disease and end-stage renal disease (ESRD), offering improved quality of life and overall survival rates. However, the limited supply of available organs makes this a scarce resource. Cardiovascular complications continue to be the leading cause of mortality in the kidney transplant population, accounting for over 30% of deaths with a functioning allograft. Thus, preoperative cardiac risk assessment is critical to optimize patient selection and outcomes. Currently there is no consensus for cardiovascular evaluation in the chronic kidney disease and ESRD population prior to kidney transplantation; the recommendations of the American Society of Nephrology and American Society of Transplantation differ from those of the American Heart Association and the American College of Cardiology. Previously developed risk scores have also been used to risk stratify this population. In this review, we discuss two cases that illustrate the difficulties of interpreting the prognostic value of current testing strategies. We also discuss the importance of different tests for cardiovascular evaluation as well as previous nonkidney transplant specific risk scores used in the pre-kidney transplant population.


Subject(s)
Cardiovascular Diseases/diagnosis , Kidney Failure, Chronic/surgery , Kidney Transplantation , Preoperative Care/methods , Cardiovascular Diseases/complications , Electrocardiography , Female , Humans , Kidney Failure, Chronic/complications , Kidney Failure, Chronic/mortality , Male , Middle Aged
7.
Kidney Int ; 75(5): 465-74, 2009 Mar.
Article in English | MEDLINE | ID: mdl-18843256

ABSTRACT

Gadolinium (Gd) based contrast agents (GBCAs) in magnetic resonance imaging (MRI) are used in daily clinical practice and appear safe in most patients; however, nephrogenic systemic fibrosis (NSF) is a recently recognized severe complication associated with GBCAs. It affects primarily patients with renal disease, such as stage 4 or 5 chronic kidney disease (CKD; glomerular filtration rate <30 ml/min per 1.73 m(2)), acute kidney injury, or kidney and liver transplant recipients with kidney dysfunction. Contrast-enhanced MRI and computed tomography (CT) scans provide important clinical information and influence patient management. An alternative contrast agent is needed to obtain adequate imaging results while avoiding the risk of NSF in this vulnerable patient group. One potential alternative is ultrasmall superparamagnetic iron oxide (USPIO) nanoparticles, which provide enhancement characteristics similar to GBCAs. We review our experience in approximately 150 patients on the potential benefits of the USPIOs ferumoxtran-10 and ferumoxytol. We focus on central nervous system (CNS) MRI but also review imaging of other vascular beds. Safety studies, including USPIO administration (ferumoxytol) as iron supplement therapy in CKD patients on and not on dialysis, suggest that decreased kidney function does not alter the safety profile. We conclude that for both CNS MR imaging and MR angiography, USPIO agents like ferumoxytol are a viable option for patients at risk for NSF.


Subject(s)
Contrast Media/adverse effects , Ferrosoferric Oxide , Iron , Kidney Diseases/complications , Magnetic Resonance Imaging/methods , Nephrogenic Fibrosing Dermopathy/prevention & control , Oxides , Central Nervous System/pathology , Chronic Disease , Dextrans , Ferrosoferric Oxide/toxicity , Gadolinium/toxicity , Glomerular Filtration Rate , Humans , Iron/toxicity , Kidney Diseases/diagnosis , Magnetic Resonance Angiography , Magnetic Resonance Imaging/adverse effects , Magnetite Nanoparticles , Male , Middle Aged , Nanoparticles/toxicity , Nephrogenic Fibrosing Dermopathy/chemically induced , Oxides/toxicity , Risk Factors
8.
Semin Dial ; 20(1): 86-90, 2007.
Article in English | MEDLINE | ID: mdl-17244129

ABSTRACT

Dialysis withdrawal is common, accounting for over 20% of patient deaths. It is the third leading cause of death among patients receiving dialysis, after cardiovascular disease and infectious complications. Here we present a case of a patient with significant comorbid disease who ultimately elected to withdraw from dialysis. The medical, social and psychological issues encountered by caregivers are reviewed. Additionally we discuss the available data on factors affecting the decision to withdraw, current practice guidelines, and efforts to educate nephrology fellows on end-of-life issues.


Subject(s)
Kidney Failure, Chronic/psychology , Renal Dialysis , Withholding Treatment , Aged, 80 and over , Comorbidity , Hospices , Humans , Kidney Failure, Chronic/therapy , Life Expectancy , Male , Motivation , Professional-Family Relations , Spouses/psychology
9.
Semin Dial ; 17(3): 237-41, 2004.
Article in English | MEDLINE | ID: mdl-15144552

ABSTRACT

We describe a patient with end-stage renal disease (ESRD) who developed depression over the period of dialysis initiation. Depression is an extremely common but underrecognized disorder in the dialysis population, which is one of the rationales for this case report. Here we present the epidemiology, mechanisms for diagnosis, associations with medical morbidity, and treatment modalities specifically for patients on dialysis.


Subject(s)
Depression/etiology , Kidney Failure, Chronic/psychology , Depression/diagnosis , Depression/therapy , Humans , Kidney Failure, Chronic/therapy , Male , Middle Aged , Renal Dialysis
10.
J Card Fail ; 9(1): 13-25, 2003 Feb.
Article in English | MEDLINE | ID: mdl-12612868

ABSTRACT

INTRODUCTION: Worsening renal function during hospitalization for heart failure, defined as elevation in creatinine during admission, predicts adverse outcomes. Prior studies define worsening renal function using various creatinine elevations, but the relative value of definitions is unknown. METHODS AND RESULTS: In a prospective cohort of 412 patients hospitalized for heart failure, we compared a spectrum of worsening renal function definitions (absolute creatinine elevations >/=0.1 to >/=0.5 mg/dL and 25% relative elevation from baseline) and associations with 6-month mortality, readmission, and functional decline. Creatinine elevation >/=0.1 mg/dL occurred in 75% of patients, and elevation >/=0.5 mg/dL occurred in 24% of patients. Risk of death rose with higher creatinine elevations (adjusted hazard ratio [HR] = 0.89, 1.19, 1.67, 1.91, and 2.90 for elevations >/=0.1 to >/=0.5 mg/dL). Maximum sensitivity of any definition for predicting mortality was 75% and maximum specificity was 79%. High creatinine elevation was a more important predictor of death than was a single measure of baseline creatinine. CONCLUSIONS: Larger creatinine elevations predict highest risk of death, yet even minor changes in renal function are associated with adverse outcomes. The choice of a "best definition" for worsening renal function has implications for the number of patients identified with this risk factor and the magnitude of risk for mortality.


Subject(s)
Kidney Diseases/blood , Kidney Function Tests , Aged , Biomarkers/blood , Cohort Studies , Connecticut , Creatinine/blood , Female , Follow-Up Studies , Heart Failure/blood , Heart Failure/mortality , Heart Failure/physiopathology , Hospitalization , Humans , Kidney Diseases/mortality , Kidney Diseases/physiopathology , Male , Middle Aged , Multivariate Analysis , Predictive Value of Tests , Prospective Studies , Risk Factors , Sensitivity and Specificity , Statistics as Topic , Stroke Volume/physiology , Survival Analysis
SELECTION OF CITATIONS
SEARCH DETAIL
...